ストックスクリーナーアプリを入手
15.25
1.49%
-0.23
アフターアワーズ：
15.25
前日終値:
$15.48
開ける：
$15.5
24時間の取引高:
2.64M
Relative Volume:
0.50
時価総額：
$11.84B
収益：
$220.00K
当期純損益:
$-1.21B
株価収益率:
-9.5081
EPS:
-1.6039
ネットキャッシュフロー:
$-387.48M
1週間 パフォーマンス:
-1.10%
1か月 パフォーマンス:
+16.86%
6か月 パフォーマンス:
-22.51%
1年 パフォーマンス:
-41.07%
1日の値動き範囲:
$14.86
$15.53
1週間の範囲:
$14.86
$16.05
52週間の値動き範囲:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.25 | 11.84B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-08 | 開始されました | Stifel | Buy |
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Underweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Neutral |
| 2025-07-01 | 開始されました | UBS | Buy |
| 2025-06-11 | 開始されました | Leerink Partners | Underperform |
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Summit Therapeutics (SMMT) Q1 2025 earnings summary - Quartr
Why is SMMT stock tumbling today? - MSN
Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary - Quartr
Price to sales forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Price to book forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
If You Invested $1,000 in Summit Therapeutics Inc (SMMT) - Stock Titan
Understanding Momentum Shifts in (SMMT) - Stock Traders Daily
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering? - Sahm
Summit Therapeutics Inc Actuals & Estimates (NASDAQ:SMMT) - TradingView
Summit Therapeutics Inc Actuals & Estimates (BMV:SMMT) - TradingView
SMMT Forecast — Price Target — Prediction for 2027 - TradingView
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics finance chief tops list of public CFO pay in 2025 - CFO.com
Bernstein raises Summit Therapeutics stock price target on trial outlook By Investing.com - Investing.com Australia
Bernstein raises Summit Therapeutics stock price target on trial outlook - Investing.com
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing - Insider Monkey
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT) - Seeking Alpha
Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Raises Target Price to $9.8 - Moomoo
Summit Therapeutics (SMMT) Q4 2025 earnings summary - Quartr
5 Most Promising Healthcare Stocks According to Wall Street Analysts - Insider Monkey
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Avoiding Lag: Real-Time Signals in (SMMT) Movement - Stock Traders Daily
Summit rebounds after nearly $50M insider purchase - MSN
Summit Therapeutics Inc (SMMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Institutional Confidence - TradingKey
Summit Therapeutics Inc (SMMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Summit Therapeutics Inc (SMMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why Summit Therapeutics Is Staying In The Biotechnology Spotlight? - Kalkine Media
Should Summit Therapeutics’ Canceled US$500 Million Equity Offering Reshape SMMT Investors’ View on Financing Strategy? - Sahm
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Investor Outlook: Evaluating A Potential 103.85% Upside - DirectorsTalk Interviews
Summit Therapeutics Raises $500 Million in Public Offering to Support Lung Cancer PipelineGAAP Earnings Report - newsline.com
SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum - timothysykes.com
Summit Therapeutics stockholders approve directors and incentive plan - The Globe and Mail
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering - Insider Monkey
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):